z-logo
open-access-imgOpen Access
EVALUATION OF ANTICANCER ACTIVITY OF PARKINSONIA ACULEATA LEAVES EXTRACT ON EHRLICH’S ASCITES CARCINOMA-INDUCED MICE.
Author(s) -
Prameela Rani A,
Agarjuna Babu E,
Prem Madhur S,
Ravi Chandra Sekhara Reddy D,
Phani Kumar K
Publication year - 2018
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2018.v11i1.22404
Subject(s) - ehrlich ascites carcinoma , lipid peroxidation , pharmacology , glutathione , hemoglobin , superoxide dismutase , ascites , biology , antioxidant , chemistry , medicine , tumor cells , biochemistry , enzyme , cancer research
 Objective: The objective of the study was to investigate the anticancer activity of the ethanolic extract of Parkinsonia aculeata (EEPA) leaves. Methods: Anticancer activity of P. aculeata (EEPA) of leaf extract was evaluated in Swiss albino mice against Ehrlich ascites carcinoma (EAC) cell line at the doses of 200 and 400 mg/kg body weight orally. The extracts were administered for 14 consecutive days. 24 h of the last dose and 18 h of fasting, the mice were sacrificed, and the anticancer effect of EEPA was assessed by evaluating tumor volume, viable and nonviable tumor cell count, tumor weight, hematological parameters, and biochemical parameters of EAC bearing mice.Results: P. aculeata extracts showed a significant decrease in (p<0.01) tumor volume, viable cell count, tumor weight, and elevated the life span of EAC bearing mice. Hematological profile such as red blood cell, hemoglobin count reverted to normal level in EEPA treated mice. The extracts significantly (p<0.05) decreased the levels of lipid peroxidation and significantly (p<0.05) increased the levels of reduced glutathione, superoxide dismutase and catalase.Conclusion: The results showed that the EEPA was effective in inhibiting the tumor growth in ascitic models and that is comparable to 5-fluorouracil. 

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here